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Prostate cancer is a leading cause of cancer-related death. The current modality of diagnosis,
the measurement of serum PSA, not only suffers from lack of specificity, but does not
distinguish clinical cases in which current treatment measures would be most successful, i.e.
aggressive, life-threatening tumors. A multiplexed MS methodology, selected reaction
monitoring-MS/MS coupled with stable isotope dilution (SID), was developed and tested in
both cells lines and clinical tissue samples. Standard curves were generated for two peptides
representing PSA and one peptide from each of two additional orthogonally validated
biomarkers, AMACR and EZH2. The standard curves show high reproducibility, sensitivity,
and good linearity. All four peptides were then measured in six clinically relevant cell lines
and are in agreement with the biochemical characteristics of each individual cell line. The
SID selected reaction monitoring-MS/MS methodology was then transferred to tissue
samples, in which the assay shows potential to differentiate benign disease from localized
cancer and localized cancer from aggressive metastatic disease. These results establish the
preliminary development of a rational targeted MS platform that strives to bridge the gap
between discovery and validation of biomarkers for the detection of prostate cancer.
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1 Introduction
Current screening and diagnosis of asymptomatic prostate
cancer (PCA) is by digital rectal examination (DRE) in
combination with the serum measurement of prostate-
specific antigen (PSA). While this combination of assays is
wrought with controversy, it still remains standard mainstay
for diagnosis of PCA. One of the major concerns regarding
the use of PSA is the unusually high rate of over-diagnosed
cancers, approximately 29% of Caucasian and 44% of Afri-
can American [1]. Worse, approximately 15% of recent
cohort participants were subsequently diagnosed with PCA
despite having below acceptable PSA threshold levels for
further diagnostic testing [2]. Hence, utilizing PSA as a
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diagnostic biomarker for PCA is in question. Now, the goal
of early detection in PCA is to find those tumors at a point at
which a cure is possible [3]. This requires biomarkers that
are not just reflective of the presence of cancer, but more,
tell the aggressive nature and possibly the lethality of the
disease.
MS-based technologies have been applied to many
discovery-based, large-scale studies and mostly applied to
the discovery of protein biomarkers, especially in the field of
cancer. Collectively these studies have produced thousands
of putative biomarkers including several specifically for PCA
[4]. Unfortunately, only a few are currently being validated
and applied in clinical diagnostics [5, 6] and none have been
validated in PCA specifically. A targeted methodology in
which to commence biomarker validation is being advanced
within the proteomics community [5, 7–9]. It is hypothe-
sized here that selected reaction monitoring MS/MS (SRM-
MS), when coupled with the introduction of stable isotopi-
cally labeled internal standards, can be developed for the
verification of putative biomarkers in PCA.
This multiplexing capability of SRM-MS has the potential
to improve diagnostic power of PCA. By combining multiple
known biomarkers as representatives for different aspects of
the disease, a new multiplexed assay could distinguish
indolent versus aggressive disease thereby targeting diag-
noses where treatment would be most successful. This work
describes the development of a new multiplexed assay
utilizing stable isotope dilution (SID) SRM-MS. Its intent is
to provide the initial step for the development, optimization,
and testing proof of principle both technically and biologi-
cally before expanding the number of markers and transi-
tioning the assay to a non-invasive biological matrix, post-
DRE urine. Included in the assay are peptides representative
of two proteins, a-methylacyl-CoA racemase (AMACR) and
enhancer of zeste homolog 2 (EZH2), which were previously
characterized as possible PCA biomarkers [10–14].
AMACR and EZH2 proteins have diverse activity and
functionality but both have been shown to be involved with
PCA in vivo and in vitro. AMACR is an enzyme involved in
the conversion of R- to S-stereoisomers and peroximsomal
b-oxidation of branched-chain fatty acids. This enzyme has
been shown repeatedly to have significant over-expression in
both the transcript and protein levels in PCA samples [11, 12].
EZH2 participates in the methylation of lysine 27 in histone
H3, which consequently leads to the repression of many
target genes [10]. It has been shown that EZH2 is over-
expressed in metastatic cancer and is a marker of aggressive
disease in clinically localized prostate tumors [14]. Therefore,
both AMACR and EZH2 were chosen as biomarkers of
aggressive disease in localized cancer and its malignant
potential. Finally, we added two peptides representative of
PSA to our panel. This was not only for proof of concept but
also in an attempt to correlate the development of this assay
to previously obtained clinical PSA ELISA values.
Once developed and optimized analytically for selectivity
and sensitivity, the assay was used to demonstrate proof of
concept measuring the approximate concentration of each
peptide in six immortalized benign and cancerous prostate cell
lines. After proof of principle and analytical feasibility was
confirmed with these cells lines, the assay was transferred to
prostate tissue samples. A total of 15 tissue samples were
utilized representing three clinical categories, five benign
(adjacent to tumor), five localized cancer (PCA), and five
metastatic tumor samples. Pooled samples for each category
were also measured by Western blot and corroborate the SID-
SRM-MS results. These four peptide markers measured with
SID-SRM-MS show potential as a panel to discriminate
between localized cancer and metastatic disease as well as
differentiating benign adjacent tissues from localized tumor.
While preliminary results are shown, we believe this is a novel
and necessary step for verification of both the multiplexed SID-
SRM-MS technology platform and of these specific peptide
biomarkers for the eventual transition of the assay to post-DRE
first void urine. It is hoped that additional markers can be
included, which will further help in distinguishing indolent
versus aggressive PCA, which will ultimately tailor treatment
options to those most in need.
2 Materials and methods
2.1 Cell line and tissue sample preparation
Collection of whole cellular protein extract from cell lines
(RWPE, PC3 DU145, 22Rv1, LnCaP, VCaP, and cancer
prostate tissue biopsy samples was done in RIPA complete
buffer (Pierce Biotechnology) supplemented with Complete
Protease Inhibitor Cocktail (Roche). Total protein extract was
quantified with bicinchoninic acid (Pierce Biotechnology).
Aliquots of 50mg of whole cellular proteins were separated by
1-D SDS-PAGE (4–12% Bis-Tris Novex-Invitrogen, Carlsbad,
CA). Twenty-four equal sized gel bands were excised and
subjected to in-gel digestion. Extracted and lyophilized
peptides were reconstituted with 12mL of 2.5 fmol/mL
(30 fmol) of each isotopically labeled peptide standard prior to
a 10mL (25 fmol of each internal standard on column) injec-
tion on-line reverse phase LC-SRM-MS (1200 Series HPLC-
CHIP, 6410 Triple Quadrapole, Agilent Technologies).
Peptides were eluted on-line to the MS-QQQ with a reverse
phase linear gradient from 97% A (0.1% Formic acid in
water) to 45% B (0.1% formic acid in acetonitrile). Western
blotting was completed in parallel with the following primary
antibodies; anti-mouse-EZH2 (BD Biosciences – 612666),
anti-mouse-AMACR (Zymed 39–4000), and anti-rabbit-PSA
(Zymed 08-0044). Goat anti-HRP IgG mouse and rabbit were
used for secondary development (Santa Cruz Biotechnology).
2.2 Clinical samples
Benign adjacent prostate and PCA tissues were obtained
from a radical prostatectomy series at the University of
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Michigan Hospitals while the metastatic PCA tissues were
obtained from the Rapid Autopsy Program, which are both
part of the University of Michigan Prostate Cancer Specia-
lized Program of Research Excellence (S.P.O.R.E) Tissue
Core. Samples were collected with informed consent and
prior institutional review board approval at the University of
Michigan. Additional detailed clinical information regarding
these tissue samples is provided in Supporting Information.
All samples were stripped of identifiers prior to assessment
and stored at 801C until use.
2.3 Method development
One ‘signature’ peptide from each of the putative protein
biomarkers, AMACR and EZH2 and an additional two
peptides from PSA were chosen to develop a multiplexed
SRM-MS assay. Detailed rational for method development is
found in Supporting Information, which briefly includes
in silicos prediction, spectra database repository and homol-
ogy search, along with ion trap analyses. The peptide from
EZH2 and one peptide from PSA were synthesized with
stably isotopically labeled C-terminal lysine resulting in a
mass difference of 8 Da. The other PSA peptide was
synthesized with stably isotopically labeled C-terminal
arginine resulting in a mass difference of 10 Da. Finally,
the peptide AMACR was synthesized with an internal
proline residue stably isotopically labeled, resulting in a
mass difference of 6 Da. Three transitions for each stably
isotopically labeled peptide were developed empirically
optimizing for both sensitivity and selectivity, data shown in
Supporting Information. Dwell time was constant at
45 msec for each transition and unit resolution was
utilized for both Q1 and Q3. Standard curves with spiked
internal standard were developed for each of the four
peptides in a background of whole cell lysate prepared as
stated above and are shown in Fig. 1A and in Supporting
Information.
The standard curve was generated as followed. Briefly,
after in-gel digestion, extracted peptides from the 24 gel
segments were re-solubilzed with serial dilutions of
each internal standard so that the following concentra-
tions of internal standard were loaded on to the column:
0 amol, 250 amol, 500 amol, 1 fmol, 5 fmol, 10 fmol, and
50 fmol. Three technical replicates of all 24 gel segments,
i.e. entire gel-lanes, were analyzed for concentrations
r1 fmol and five technical replicates were completed for
concentrations Z5 fmol. A five point concentration
standard curve was then generated for each peptide. Indi-
vidual replicate measurement of AUCs are summed across
the 24 fractions and transformed into logarithmic scale for
ease of interpretation before being plotted. A linear trend
line was then drawn for the average log(2) value and a
correlation coefficient calculated. All raw data and plots
without logarithmic transformation are included in
Supporting Information.
2.4 Data analysis
Ion chromatograms for each transition were extracted with a
symmetric expansion of m/z 70.1. Each extracted ion
chromatogram (EIC) was then smoothed with a Gaussian
function of 15 points width. Peak areas for each transition
were calculated utilizing default MS/MS integration. Peak
areas were filtered to remove any peaks o10% of largest
peak and a signal-to-noise ratio (height:peak-to-peak) of 5.
Each transition passing the above filters and inside a
retention time drift of 10% was manually verified. The
filtered peak areas were then summed over each experiment
(24 segments), and a ratio, standard deviation, coefficient of
variation, and 95% confidence level with upper and lower
limits for each heavy:light transition pair is calculated.
While each transition was summed for every gel lane, i.e. all
24 segments, appreciable signals were only found in one to
three gel segments in and surrounding the region of
expected molecular weight for the protein.
3 Results and discussion
Current diagnostic and prognostic tests for PCA have low
specificity. This work describes the development of a
multiplexed MS methodology for PCA that strives to be
more specific, i.e. distinguishing indolent from aggressive
disease. Peptides targeted for this assay were chosen from
three different proteins, AMACR, EZH2, and PSA. We
believe that the combination of these three proteins offer a
newer, more rational manner in which to characterize PCA
and a starting point to develop a more targeted methodology
to detect life-threatening disease, that is, the goal of not just
detecting the presence of indolent disease, but to detect the
aggressive nature of the disease. AMACR could mark both
the presence of an aggressive localized tumor and possibly
the transition from a localized to more metastatic disease.
Additionally, EZH2 appears to be a biomarker for an
aggressive form of PCA. Finally, PSA was included in these
studies as a proof of concept. PSA is well characterized in
both the cells lines and metastatic clinical samples used in
this work. Further, we know that PSA levels decrease upon
current PCA treatments.
3.1 Method development
Method development consisted of both in silicos and
empirical means iteratively, each guiding the other until the
final peptide analytes were chosen and optimized for
selectivity and sensitivity. Each of the proteins were theo-
retically digested and fragmented to predict both precursor
and product ions. Predicted peptides were then compared
with the listing of observed peptides in the Global Proteome
Machine (GPM – http://www.thegpm.org/) database.
Several peptides were found in the GPM database for PSA
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and EZH2; however, none were found for AMACR. Because
there were no entries for AMACR in the GPM and the
unknown influence of in-gel digestion and peptide extrac-
tion, recombinant proteins were analyzed by gel-LC MS/MS
on an ion trap. The Method Development Appendix
contains the detailed methodologies and tabulated results of
both experimental and in silico findings. This iterative
process revealed a rationale for culling possible peptide
candidates, either predicted or observed, from further
method development in the following manner:
(a) Peptides with precursor ions predicted to have a mass
outside the mass range of the QQQ were removed.
(b) Peptides that were predicted or observed with a missed
cleavage site, a cysteine, methionine, or N-terminal
glutamine or glutamate were removed due to the
possible variability of experimental modification and
artifacts.
(c) Peptides observed experimentally and in the GPM
database were then searched in protein BLAST for
homology.
This iterative culling revealed a listing of two peptides for
EZH2 and three peptides for AMACR to be reasonable
candidates for SRM development. Finally, manual inspec-
tion of the ion trap spectra resulted in a peptide for each
protein that optimized for sensitivity in both precursor and
product ion spectra, shown in Supporting Information.
These peptides were then transferred to the QQQ utilizing
synthesized isotopically labeled heavy amino acid. Peptides
for PSA were initially chosen directly from the literature
[7, 15]; and, ion trap analysis of the PSA protein confirmed
the successful digestion and extraction of the published
peptide sequences. Not surprisingly, both peptides utilized
for PSA were indeed in the GPM database, however; the
final peptide for EZH2 was not listed, nor were any peptides
listed for AMACR. This suggests that while looking at
experimentally collected data repositories for initial method
development may be an advantageous time saver, one
may not always obtain the best peptide for SRM method
development.
Then, method development commenced on the QQQ for
each heavy peptide empirically. Both fragmentor (voltage
applied to the exit end of the capillary) and collision energy
were empirically optimized for greatest response, see
Supporting Information. Each corresponding non-isotopi-
cally labeled transition was then added to the instrument
method for optimization of dwell time, ensuring for good
peak shape, a minimum of 15 points, and a maximum of 25
points across the curve.
1 fmol 5 fmol 10 fmol 50 fmol 500 amol 1 fmol 5 fmol 10 fmol 50 fmol





Figure 1. (A) Standard curve for each peptide. For each internal standard, a five concentration (0.5, 1, 5, 10, and 50 fmol) standard curve
was developed over a background matrix of VCaP whole cellular lysate. Three technical replicates for 500 amol, and five technical
replicates for the additional four concentrations are plotted against the log2 translated integrated areas under the curve (AUCs are
summed over the 24 fractions) and are represented as black dashes. Averages of those measurements are shown as red diamonds. A
linear regression trend line is drawn with indicated R2 values. (B) Schematic representation for migration of proteins in 1-D SDS-PAGE.
Peptide biomarkers were reproducibly measured by this SID-SRM-MS methodology in 1-D SDS PAGE fractions corresponding at and near
the respective protein’s molecular weight.
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Because the chosen marker proteins, AMACR and EZH2,
are expected to be expressed almost ubiquitously in all
suitable, analytically comparable, and similar matrixes,
empirical method development was completed only on the
synthesized heavy peptides. This is in contrast to the
method development described by Addona et al., [7],
whereby the recombinant light protein and the heavy
labeled internal standard peptide are both spiked into the
matrix, devoid of endogenous analyte. We feel this approach
was not practical in our study as each peptide marker
utilized is expected to be detected as a normal endogenous
analyte. It is the relative, differential expression of these
markers that are biologically significant.
Finally, standard curves for each peptide were generated
measuring the heavy peptides in a background of in-gel
separated and digested whole cellular lysate matrix to
determine approximate sensitivity, selectivity, and linear
range of response for each transition. Unfortunately, one
peptide from PSA initially chosen for empirical method
development did not respond appropriately for sensitivity
and was removed from further method development.
Shown in Fig. 1A are the summarized results of three
replicate measurements for 500 attattmole and five replicate
measurements for the remaining increasing concentrations.
The approximate LOD of the peptides representing EZH2,
AMACR, and one peptide in PSA appears to be approxi-
mately 500 attmol and 1 fmol for the other peptide in PSA.
The matrix was also analyzed without the addition of any
internal standards (0 attmol) for which no signal for the
internal standards was observed. While not absolute, we
believe this to be indicative of good selectivity for the chosen
transitions. The calculation of CV in both linear and loga-
rithmic space is shown in the Supporting Information. For
both EZH2 and AMACR, at least one transition at
500 attmol had a calculated CV of r20%, while both
peptides in PSA had at least one transition with a calculated
CV r20% at 1 fmol. Of important note, gel fractionation of
whole cellular proteins was found to be necessary for
achieving sensitive and selective detection of each peptide in
the complex matrix, data not shown. Furthermore, the
percent yield of recovering each peptide from in-gel frac-
tionation and tryptic digestion was not determined and
calculated. Therefore, this work describes an approximation
of quantification, not absolute quantification. This is on-
going and future necessary work.
3.2 Cell lines
Having completed the analytical method development, proof
of principle was completed for the peptide biomarkers in
cell lines. There was initial concern measuring one peptide
for each of the EZH2 and AMACR protein given the valid
argument by Duncan et al. [9]. Shown in Fig. 1B is a sche-
matic representation of where, with regard to migration in
the 1-D SDS-PAGE gel, each peptide was repeatedly
measured in all cell lines and tissue samples. The observa-
tion that each peptide was measured in the molecular
weight region of the respective protein provides confidence
that these peptides are good representatives of the protein.
However, throughout this text, the term peptide biomarkers
will be utilized since this method clearly does not measure
the entire protein moiety.
Figure 2 shows EIC for each of the peptides measured. In
red are EICs for the spiked internal standard (25 fmol) and
in black are the endogenous measurements corresponding
to the non-isotopically labeled peptides. All six transitions
overlap in retention time and are in agreement in relative
ratio to one another. Utilizing fewer transitions per peptide
would negate or decrease this confidence [16, 17].
Six immortalized cells lines were then used to provide
proof of principle for the methodology. Three biological
replicate experiments for each cell line were completed.
RWPE cells are histologically normal adult human prostate
epithelial cells and as such were used as a pseudo negative
control for the four peptide biomarkers measured. The data
showed negligible or no detection for each of the peptide
biomarkers measured; approximately 3.79 fmol for EZH2
and 500 attmol per 50 mg of whole cellular lysate for AMACR
while non-detectable for both PSA peptides. PC3 cells are
prostate adenocarcinoma cells and showed a similar trend;
an average of 6.83 fmol for EZH2 and 3.76 fmol for AMACR
but again non-detectable for both PSA peptides. Similar
results were obtained for DU145 cells, a PSA negative,
epithelial prostate carcinoma cells. Average concentration
per 50 mg of whole cellular lysate was 4.54 fmol for EZH2
and 5.50 fmol for AMACR while non-detectable for both
PSA peptides as expected. Interestingly, in 22Rv1 cells, a
higher concentration was measured for all four peptide
biomarkers, 14.07 fmol for EZH2, 15.86 fmol for AMACR,
and 10.82 fmol and 17.91 fmol for both peptides in PSA per/
50 mg. 22Rv1 cells are known to express PSA and are much
more aggressive, which corresponds to our SID-SRM-MS
results. Both LnCaP and VCaP cells are from highly
aggressive PCA metastases, lymph node and bone, respec-
tively. Both cell lines are known to express PSA. Peptide
biomarkers for EZH2, AMACR, and both peptides in PSA
were measured at 8.66, 22.67, and 89.89 and 176.00 fmol/
50 mg of total cellular protein, respectively, in LnCaP cells.
While the same peptides measured 3.85, 16.76, 20.98, and
36.18 fmol, respectively per 50mg of total cellular protein in
VCaP cells. These results are shown in Fig. 3. Shown below
each line graph are Western blot analysis for each protein
and a Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
loading control, which correlate the SID-SRM-MS results,
further providing confidence that these peptide biomarkers
are indeed good representation of their respective proteins.
First, these cell line results demonstrate a proof of prin-
ciple. This SID-SRM-MS methodology can accurately
measure the presence or absence of PSA. As characterized
by the American Type Tissue Culture (ATCC, Manassas,
VA) the following cell lines do not express PSA: RWPE,
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PC3, and DU145 while the following do: 22Rv1, LnCaP, and
VCaP. Our SID-SRM results emulate exactly that. Secondly,
these results demonstrate that a panel of peptide biomarkers
may provide a mechanism in which to tease out the intrinsic
molecular properties specific to the peculiarities of PCA. For
instance, in RWPE, PC3, and DU145 cells, both EZH2 and
AMACR were measured at lower levels, suggesting a loca-
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Figure 2. SID-SRM-MS traces of each
peptide measured. EIC of spiked
heavy peptide standard is outlined in
red. EIC of light, i.e. endogenous
peptide are in black. All six extracted
transitions (three from heavy internal
standard and three from endogen-
ous) must overlap in retention time
and be in relational agreement one
another, as shown in the magnified
version (left panel), to be considered
a positive measurement. Representa-
tive EICs are taken from the most
abundant fraction for each peptide.
Both PSA peptides and the AMACR
peptide were measured in LnCaP cells
while EZH2 peptide was measured in
22Rv1 cells is shown.
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the higher measurements of AMACR in the aggressive,
metastatic cell lines, 22Rv1, LnCaP, and VCaP. Interest-
ingly, 22Rv1, an aggressive, hormone-independent cell line,
showed very high levels of AMACR. This suggests that very
high levels of AMACR may be indicative of hormone inde-
pendence. Finally, it was surprising to see the low levels of
EZH2 in the VCaP cell line. We speculate the following
biological rationale for this finding. EZH2 is a histone
methyl transferase that generally confers transcriptional
repressional activity. It is hypothesized that the VCaP cell
line contains so much gross genomic instability that the
epigenetic transcription regulation is no longer a principle
part of its cancerous properties.
3.3 Tissues samples
Next, the assay was transferred to clinical tissue samples,
either prostate biopsy cores directly from histological posi-
tive localized tumor cells and adjacent benign tissue or
samples taken from the location of major metastases at
autopsy. A summary of results are shown in Fig. 4. Box
plots show the range and average concentration of each
peptide biomarker for each category of tissue samples.
Below the box plots are Western blots for the target protein
measured in pooled tissues samples for each category. As
shown, the Western blots correlate the SID-SRM-MS
measurements. Strikingly, the peptide biomarkers, EZH2
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Figure 3. Proof of principle for SID-SRM-MS analysis with
immortalized cells lines. Line graphs show the approximate
concentrations for three biological replicates (black dashes) with
an average and trend line (red diamonds and red dashed line,
respectively) in six immortalized cell lines. Western blots for all
three proteins are shown below respective line graphs with










Figure 4. Measurement of peptide biomarkers in tissues. Box
plots for the approximate concentration of each peptide
biomarker measured in pooled tissue samples with SID-SRM-
MS. Western blots for each of the respective proteins are shown
below box plots.
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non-statistically significant, in the metastatic tissue samples
when compared with both benign adjacent and the localized
tumor. Additionally, the concentration of EZH2, AMACR,
and PSA show an increase, again not statistically significant,
from benign adjacent to localized tumor. As expected, the
concentration of PSA decreases (po0.01) with metastasis
due to treatment initiation of these patients prior to death. It
is believed that additional samples will increase the statis-
tical significance of these preliminary findings.
Contained in the Supporting Information are the serum
ELISA PSA results for the five metastatic samples
measured. For purposes of correlating the two measure-
ments, it is prudent to use the ELISA value at time of death
as the tissue samples were taken at autopsy. It is, however,
very difficult to directly compare the ELISA results with the
SID-SRM-MS results due to the different locations of the
sample matrix. It is expected that there is biotransformation
and various protein kinetics adversely affecting a correlation
of the different measurement simply because of diverse
sample locations. This is in contrast to the excellent corre-
lative work by Fortin et al. where both ELISA and MS
measurements for PSA were taken in the serum [15, 18].
While we believe these issues prevent direct comparison, the
data does show a general correlation as the patients, M1 and
M3, with the highest serum ELISA values, 928 and 3776 ng/
mL, also show the highest PSA SID-MRM-MS results, 93
and 67 fmol/50 mg of total protein, respectively. These PSA
values, however, do not correlate with the total Gleason
score. Patient M4 had a total Gleason score of 9 with a
relatively low SID-MRM-MS (0.25 fmol/50 mg of total
protein) and ELISA PSA value (189 ng/mL), while patient
M3, with the highest ELISA and SID-MRM-MS PSA values,
had a total Gleason score of 7. Furthermore, all normal and
localized tumor samples have a total Gleason score of 7,
despite sometimes very high SID-MRM-MS results. This we
feel further argues the need for more discriminatory means
of diagnoses. Intriguingly, the two different peptide
measurements for PSA are in agreement with one another.
In Fig. 5, the measured concentrations of each peptide
representing PSA are shown. This figure illustrates that
while measurements were obtained for each individual
peptide, one or the other could be used singly in the
multiplexed assay as each peptide separately show roughly
equivalent results.
4 Concluding remarks
This work describes the preliminary development of a peptide
biomarker assay utilizing SID-SRM-MS for PCA. The assay
concentrates on four peptide biomarkers that are repre-
sentatives of known protein biomarkers of PCA. We believe
these results are both novel with regard to the multiplexed
detection of known biomakers of PCA and technologically
advanced, representing a preliminary development of an SID-
SRM-MS assay utilized on clinical samples. While preli-
minary assay development and subsequent results show
promise, further study demonstrating the percent recovery
during sample preparation and utilizing the assay on addi-
tional tissue samples will be required to demonstrate statis-
tical significance and clinical feasibility. Future work is also
ongoing, which includes the addition of several more peptide
biomarkers and the technical transition to urine. More
peptide biomarkers can be added, which will aid in the
detailed delineation of clinical cases necessitating more
personal tailored treatment options. Finally, we believe that a
multiplexed SID-SRM-MS assay has the potential to achieve a
higher discriminatory power for the detection of PCA than
PSA alone or in combination with DRE.
The authors have declared no conflict of interest.
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